Vimarsana
Biggest News Aggregation in the World

Page 11 - Project Bioshield News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Project Bioshield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Project Bioshield Today - Breaking & Trending Today

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma - Vimarsana News

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Published: April 3, 2023

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Source: prnewswire.com
Related Topics:
United StatesChristopherj SchaberUs CongressSoligenix IncNational Institute Of AllergyWhile The CompanyDefense Threat Reduction AgencyDevelopment AuthorityUs DevelopmentEuropean Medicines AgencyBiomedical Advanced ResearchExchange CommissionOur Public Health SolutionsDrug AdministrationPrnewswire Soligenix IncOutcome ExpectedChief Executive OfficerAbout Cutaneoust Cell LymphomaPublic Health SolutionsNational InstituteInfectious DiseasesProject BioshieldPriority Review Voucher
Soligenix, Inc.: Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results - Vimarsana News

Soligenix, Inc.: Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results

Published: March 31, 2023

PRINCETON, N.J., March 31, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products

Source: finanznachrichten.de
Related Topics:
United StatesNew JerseyChristopherj SchaberStefan KlotterJersey Economic Development AuthorityOur Public Health SolutionsDefense Threat Reduction AgencyJersey Technology Business Tax CertificateExchange CommissionWhile The CompanyPrnewswire Soligenix IncPaycheck Protection ProgramDevelopment AuthorityBiomedical Advanced ResearchNational Institute Of AllergyDrug AdministrationUs CongressSoligenix IncUs DevelopmentChief Executive OfficerSeriesd Preferred StockStandard TimeNew Jersey Economic Development AuthorityEnded DecemberPublic Health Solutions
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results - Vimarsana News

Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results

Published: March 31, 2023

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Source: prnewswire.com
Related Topics:
United StatesNew JerseyChristopherj SchaberUs DevelopmentJersey Technology Business Tax CertificateDefense Threat Reduction AgencyDevelopment AuthoritySoligenix IncJersey Economic Development AuthorityDrug AdministrationUs CongressPrnewswire Soligenix IncOur Public Health SolutionsBiomedical Advanced ResearchExchange CommissionNational Institute Of AllergyWhile The CompanyPaycheck Protection ProgramChief Executive OfficerSeriesd Preferred StockStandard TimeNew Jersey Economic Development AuthorityYear Ended DecemberPublic Health SolutionsNational Institute
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million - Vimarsana News

Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

Published: March 16, 2023

16.03.2023 - - NUZYRA (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year - Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax ...

Source: wallstreet-online.de
Related Topics:
United StatesChristine FanelleEvan LohHans VitzthumUs Department Of HealthZai LabParatek Pharmaceuticals IncDevelopment AuthorityBioshield Anthrax ProgramExchange CommissionHuman Service Biomedical Advanced ResearchDevelopment ProgramDevice AgencyRare Disease ProgramProject BioshieldTuberculous MycobacteriaMedical Device AgencyInvestor RelationsParatek PharmaceuticalsAnnual ReportConsolidated Statement
The Remnant Newspaper - "I Am 100% Convinced That It's Biological Warfare": Lieutenant Colonel Pete Chambers' Special Interview with The Remnant - Vimarsana News

The Remnant Newspaper - "I Am 100% Convinced That It's Biological Warfare": Lieutenant Colonel Pete Chambers' Special Interview with The Remnant

Published: February 17, 2023

Lieutenant Colonel Pete C. Chambers was in the United States Army in two major stints inside a period of thirty-nine years. He enlisted at the age of...

Source: remnantnewspaper.com
Related Topics:
United StatesNew MexicoThe White HouseDistrict Of ColumbiaNational DefenseRepublic Of ChinaTaiwan GeneralWest VirginiaFranciss CollinsLee MerrittDonald TrumpGeorgew BushsetMark MilleyVernon ColemanAnthony FauciPeter McculloughDavid MartinSteve KirschLos AngelesRobert MaloneSasha LatyapovaRobertw MaloneMichael FlynnPeter ColdwellPeter Daszak